Buy4

Cytosorbents Corp

CTSO

Total Value

$22.6K

Net $22.6K bought

Filing Date

Sep 16, 2026

1 transaction

Purchases

$22.6K

1 transaction

Trade Summary

On Sep 15, 2026, Chan Phillip P., Chief Executive Officer, Director, purchased $22.6K of Cytosorbents Corp (CTSO) across 1 transaction. The filing covers Common Stock and reflects net buying of $22.6K. Reported prices ranged from $6.00. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.

Price at the Time of the Trade

CTSO daily price with the insider's purchase marked at $6.00.

Bought near the 6-month high · about level with today's price.

Price data is delayed and provided for context only — not investment advice.

Insider Information

Name: Chan Phillip P.
Role: Chief Executive Officer, Director
Location: PRINCETON, NJ

Filing Details

Filing Date: Sep 16, 2026
Transaction Date: Sep 15, 2026
Accession Number: 0001104659-26-108326
Form Type: 4
Net Trading Amount: $22.6K

Non-Derivative Transactions

Date	Security	Shares	Price	Type	Value
Sep 15, 2026	Common Stock	3,774	$6.00	Purchase	$22.6K

Want live alerts when Chan Phillip P. trades again?

Download Insider Trades to track CTSO, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.

iOS App Android App

Footnotes

(F1)This transaction reported on this Form 4 reflects an open market purchase made by the Reporting Person.
(F2)Includes: (i) the following restricted stock units ("RSUs") that will be settled into shares of Common Stock upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Issuer") as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 515 RSUs granted on March 15, 2018, (b) 935 RSUs granted on February 24, 2017, (c) 2,850 RSUs granted on June 7, 2016 and (d) 6,500 RSUs granted on April 8, 2015;
(F3)(continued from footnote 2) (ii) 2,640 RSUs of 5,280 granted on August 8, 2025, which vest in equal parts at the first and second year anniversaries of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date, and (iii) 83,782 shares of Common Stock owned by the Reporting Person.
(F4)Reflects the 1-for-20 reverse stock split effected by the Issuer on September 8, 2026.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chan Phillip P.

(Last)

(First)

(Middle)

C/O CYTOSORBENTS CORPORATION

305 COLLEGE ROAD EAST

(Street)

PRINCETON

08540

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Cytosorbents Corp [ CTSO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/15/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	09/15/2026		P		3,774⁽¹⁾	A	$6	100,996⁽²⁾⁽³⁾⁽⁴⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This transaction reported on this Form 4 reflects an open market purchase made by the Reporting Person.

2. Includes: (i) the following restricted stock units ("RSUs") that will be settled into shares of Common Stock upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Issuer") as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 515 RSUs granted on March 15, 2018, (b) 935 RSUs granted on February 24, 2017, (c) 2,850 RSUs granted on June 7, 2016 and (d) 6,500 RSUs granted on April 8, 2015;

3. (continued from footnote 2) (ii) 2,640 RSUs of 5,280 granted on August 8, 2025, which vest in equal parts at the first and second year anniversaries of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date, and (iii) 83,782 shares of Common Stock owned by the Reporting Person.

4. Reflects the 1-for-20 reverse stock split effected by the Issuer on September 8, 2026.

	/s/ Phillip P. Chan	09/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Form 4 as rendered by the SEC from accession 0001104659-26-108326.

Cytosorbents Corp

Trade Summary

Price at the Time of the Trade

Company Information

Insider Information

Filing Details

Non-Derivative Transactions

Want live alerts when Chan Phillip P. trades again?

Footnotes

SEC Form 4

SEC Filing

Price at the Time of the Trade

SEC Form 4